ReviewLancet (London, England)2023
Monkeypox.
Review in Lancet (London, England), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. It is linked to 2 registered trials, which are not on this map. Cited by 275 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Randomized Trial to Evaluate the Efficacy/Effectiveness, Safety, and Immunogenicity of Replicative Live Attenuated Vaccinia Virus Vaccine LC16m8 for Prevention Against Mpox in High-risk Populations During Vaccination Deployment in Colombia
Understanding MPXV Viral Clearance in Mpox Patients and Evaluating Transmission Dynamics of MPXV and Mpox Vaccine Effectiveness in West Africa : The Republic of Guinea
Who cites it
275 citing papers in PubMed, 4 syntheses or guidelines pooled it, 527 citations in OpenAlex.
- Prevalence of mpox infection among men who have sex with men: a systematic review and meta-analysis.Infectious diseases of poverty · 2026Pooled it
- Containment and response strategies for mpox outbreaks: a systematic review.BMC infectious diseases · 2025Pooled it
- Prevention of sexual transmission of mpox: a systematic review and qualitative evidence synthesis of approaches.Infectious diseases (London, England) · 2024Pooled it
- Paediatric, maternal, and congenital mpox: a systematic review and meta-analysis.The Lancet. Global health · 2024Pooled it
- Differential pathogenesis and antiviral treatment outcomes of MPXV clade Ib and clade IIb in a BALB/c mouse model.Emerging microbes & infections · 2026Article
- Molecular cloning of a monkeypox virus clade IIb genome and construction of an attenuated mutant for basic and translational research.Emerging microbes & infections · 2026Article
- Rapid diagnosis, genome sequencing and culture isolation of a monkeypox virus of clade Ib from a Ugandan during a professional stay in France.IJID regions · 2026Article
- Understanding Mpox Knowledge, Communication, and Care Engagement Among Black and Latino Gay and Bisexual Men.AIDS patient care and STDs · 2026Article
- A comprehensive overview of monkeypox virus disease.Tropical medicine and health · 2026Review
- History of sexually transmitted infections among mpox cases in the 2022 outbreak in Spain.HIV medicine · 2026Article
- Monkeypox Virus Surveillance - United States, 2024-2025.MMWR. Morbidity and mortality weekly report · 2026Article
- Article
- An in-depth comparison: first wave of mpox in Rio de Janeiro, Brazil and Lisbon, Portugal.BMC infectious diseases · 2026Article
- Overcoming Transmission Barriers: A Dual-Functional Adhesive Hydrogel for Direct Monkeypox Virus Neutralization and Wound Healing.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- CRISPR-Cas12a-based fluorescent and visual assays for universal detection and clade discrimination of mpox virus.Microbiology spectrum · 2026Article
- Distinct Inflammatory Immune Signature in Acute Mpox Associated With Proctitis.Open forum infectious diseases · 2026Article
- Observational
- Rethinking mpox: epidemiology, clinical variants, diagnosis, and response.Osong public health and research perspectives · 2026Article
- MMF inhibits poxvirus infection by disrupting IMPDH2 interaction with USP5 and inducing its rod-and-ring assemblies.Virologica Sinica · 2026Article
- From clinical fluids to environmental matrices: quantitative monitoring of infectious monkeypox virus based on PMA-qPCR during the Guangdong outbreak.Tropical medicine and health · 2026Article
215 more citing papers are in PubMed but not listed here.
Corrections and comments
- Erratum issued
Authors and funding
7 authors at 7 institutions in 6 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Monkeypox is a zoonotic illness caused by the monkeypox virus, an Orthopoxvirus in the same genus as the variola, vaccinia, and cowpox viruses. Since the detection of the first human case in the Democratic Republic of the Congo in 1970, the disease has caused sporadic infections and outbreaks, mainly restricted to some countries in west and central Africa. In July, 2022, WHO declared monkeypox a Public Health Emergency of International Concern, on account of the unprecedented global spread of the disease outside previously endemic countries in Africa and the need for global solidarity to address this previously neglected disease. The 2022 outbreak has been primarily associated with close intimate contact (including sexual activity) and most cases have been diagnosed among men who have sex with men, who often present with novel epidemiological and clinical characteristics. In the 2022 outbreak, the incubation period ranges from 7 days to 10 days and most patients present with a systemic illness that includes fever and myalgia and a characteristic rash, with papules that evolve to vesicles, pustules, and crusts in the genital, anal, or oral regions and often involve the mucosa. Complications that require medical treatment (eg, antiviral therapy, antibacterials, and pain control) occur in up to 40% of patients and include rectal pain, odynophagia, penile oedema, and skin and anorectal abscesses. Most patients have a self-limited illness; between 1% and 13% require hospital admission (for treatment or isolation), and the case-fatality rate is less than 0·1%. A diagnosis can be made through the presence of Orthopoxvirus DNA in PCRs from lesion swabs or body fluids. Patients with severe manifestations and people at risk of severe disease (eg, immunosuppressed people) could benefit from antiviral treatment (eg, tecovirimat). The current strategy for post-exposure prophylaxis or pre-exposure prophylaxis for people at high risk is vaccination with the non-replicating modified vaccinia Ankara. Antiviral treatment and vaccines are not yet available in endemic countries in Africa.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.